^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Enlituo (cetuximab biosimilar)

    i
    Other names: CMAB009, CMAB 009, STI-001
    Associations

    News

    Trials
    Company:
    Mabpharm Limited, Simcere, Sorrento
    Drug class:
    EGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    17d
    CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=520, Completed, Taizhou Mabtech Pharmaceutical Co.,Ltd | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF wild-type
    |
    irinotecan • leucovorin calcium • fluorouracil topical • Enlituo (cetuximab biosimilar)
    8ms
    CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=520, Active, not recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd | Trial completion date: Jun 2023 --> Jun 2024
    Trial completion date • Metastases
    |
    BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF wild-type
    |
    irinotecan • leucovorin calcium • fluorouracil topical • Enlituo (cetuximab biosimilar)
    2years
    CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=520, Active, not recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd | Trial completion date: Jun 2022 --> Jun 2023
    Trial completion date • Metastases
    |
    BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF wild-type
    |
    irinotecan • leucovorin calcium • fluorouracil topical • Enlituo (cetuximab biosimilar)
    3years
    CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=520, Active, not recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    5-fluorouracil • irinotecan • leucovorin calcium • fluorouracil topical • Enlituo (cetuximab biosimilar)
    3years
    CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=512, Recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd | Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Oct 2021 --> Mar 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    5-fluorouracil • irinotecan • leucovorin calcium • fluorouracil topical • Enlituo (cetuximab biosimilar)
    4years
    CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=512, Recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd | Trial completion date: Apr 2021 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Oct 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    5-fluorouracil • irinotecan • leucovorin calcium • fluorouracil topical • Enlituo (cetuximab biosimilar)